Avelumab Dose Selection for Clinical Studies in Pediatric Patients with Solid Tumors

BACKGROUND AND OBJECTIVE: A phase I/II trial evaluated the safety, antitumor activity, and pharmacokinetics of avelumab (anti-PD-L1 antibody) in pediatric patients with refractory/relapsed solid tumors (NCT03451825). This study aimed to inform avelumab dose selection in pediatric populations using p...

Descripción completa

Detalles Bibliográficos
Autores principales: Vugmeyster, Yulia, Grisic, Ana-Marija, Brockhaus, Brigitte, Rueckert, Peter, Ruisi, Mary, Dai, Haiqing, Khandelwal, Akash
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9287219/
https://www.ncbi.nlm.nih.gov/pubmed/35484319
http://dx.doi.org/10.1007/s40262-022-01111-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9287219/
https://www.ncbi.nlm.nih.gov/pubmed/35484319
http://dx.doi.org/10.1007/s40262-022-01111-8

Ejemplares similares